Asociación entre la anticoagulación bajo diferentes rangos de tiempo parcial de tromboplastina (PTT) y el desarrollo de complicaciones hemorrágicas en adultos durante el soporte de oxigenación por membrana extracorpórea (ECMO). Un estudio de cohorte retrospectivo
dc.contributor.advisor | Pardo Turriago, Rodrigo | spa |
dc.contributor.author | Garzón Ruiz, Jenny Paola | spa |
dc.contributor.orcid | Garzón Ruiz, Jenny Paola [0000-0001-7889-0929] | spa |
dc.date.accessioned | 2024-07-17T15:58:30Z | |
dc.date.available | 2024-07-17T15:58:30Z | |
dc.date.issued | 2024 | |
dc.description | ilustraciones, diagramas | spa |
dc.description.abstract | Introducción: en el soporte de oxigenación por membrana extracorpórea (ECMO), se cuenta con la guía de anticoagulación para el paciente adulto y pediátrico del año 2021, sin embargo, las instituciones pueden tomar la decisión de generar sus propios protocolos institucionales. Al no existir evidencia sólida resulta indispensable conocer si anticoagulación de mantenimiento bajo diferentes rangos de PTT utilizando heparina no fraccionada (HNF) y sin anticoagulación está asociada al desarrollo de complicaciones hemorrágicas en adultos. Objetivo: Determinar la asociación entre la anticoagulación de mantenimiento bajo diferentes rangos de PTT en adultos con HNF y adultos sin anticoagulación; y el desarrollo de complicaciones hemorrágicas en adultos durante el soporte de ECMO a fin de establecer si la anticoagulación incrementa el riesgo de aparición del evento. Diseño: estudio cuantitativo, observacional y analítico de cohorte retrospectivo. Población y muestra: adultos que recibieron soporte ECMO en la Fundación Clínica Shaio (FCS) en el periodo 2018-2023. Análisis estadístico: se usó estadística descriptiva para reportar las variables cuantitativas. Se utilizaron medidas de tendencia central y de dispersión de acuerdo con la distribución identificada por el sesgo y el apuntalamiento. Las diferencias entre grupos fueron estimadas con ANOVA o Kruskall Wallis según corresponda. Las variables cualitativas dicotómicas y politómicas fueron descritas mediante frecuencias absolutas y proporciones. Entre grupos se estimaron diferencias mediante las pruebas chi cuadrado o Fisher, de acuerdo con las frecuencias esperadas en las celdas. Se utilizaron curvas de Kaplan-Meier para comparar el riesgo del evento hemorrágico en función del tiempo. La asociación se estimó mediante Hazard Ratio (HR) y el riesgo con un modelo multivariado de riesgos proporcionales de Cox ajustado por covariables. Resultados: se incluyeron 277 adultos con mediana de edad de 42.42 años, mayor proporción de hombres (64.98%) y con mayor frecuencia un diagnóstico principal de síndrome de dificultad respiratoria aguda (SDRA) con un 65.70%. Respecto al desenlace de interés el riesgo en función del tiempo de presentar complicaciones hemorrágicas durante el soporte ECMO para el grupo con HNF y con PTT superior a 70 es 2.97 veces mayor en comparación con no utilizar HNF (IC 95%: 1.53 - 5.77; p=0.001). Conclusiones: existe asociación entre las metas de PTT y el desarrollo de complicaciones hemorrágicas; el riesgo de presentar complicaciones hemorrágicas se incrementa 2.97 veces al mantener metas de PPT >70 segundos durante el soporte ECMO. No usar HNF durante el soporte ECMO y anticoagular con metas superiores a 60 segundos, clínicamente incrementa el riesgo de aparición eventos hemorrágicos. Por lo tanto, la recomendación es mantener un PTT máximo de 70 segundos con o sin HNF durante el soporte ECMO en adultos. (Texto tomado de la fuente). | spa |
dc.description.abstract | Introduction: in extracorporeal membrane oxygenation (ECMO) support, there are anticoagulation guidelines for adult and pediatric patients for the year 2021; however, institutions may decide to generate their own institutional protocols. In the absence of solid evidence, it is essential to know whether maintenance anticoagulation under different PTT ranges using unfractionated heparin (UFH) and without anticoagulation is associated with the development of hemorrhagic complications in adults. Objective: to determine the association between maintenance anticoagulation under different TTP ranges in adults with UFH and adults without anticoagulation; and the development of hemorrhagic complications in adults during ECMO support in order to establish whether anticoagulation increases the risk of occurrence of the event. Methodological design: quantitative, observational, analytical, retrospective cohort study. Population and sample: adult who received ECMO support at FCS in the period 2018-2023. Sample of 277 adults. Statistical analysis: descriptive statistics were used to report the quantitative variables. Measures of central tendency and dispersion were used according to the distribution identified by bias and underpinning. Differences between groups were estimated with ANOVA or Kruskall Wallis as appropriate. Dichotomous and polytomous qualitative variables were described using absolute frequencies and proportions. Differences between groups were estimated using chi-square or Fisher's exact tests, according to the expected frequencies in the cells. Kaplan-Meier curves were used to compare the risk of the bleeding event as a function of time. The association was estimated using Hazard Ratio (HR) and risk with a multivariate Cox proportional hazards model adjusted for covariates. Results: included 277 adults with a median age of 42.42 years, a higher proportion of men (64.98%) and with a higher frequency of a main diagnosis of acute respiratory distress syndrome (ARDS) with 65.70%. Regarding the outcome of interest, the time-dependent risk of hemorrhagic complications during ECMO support for the group with UFH and PTT greater than 70 is 2.97 times higher compared to not using UFH (95% CI: 1.53 - 5.77; p=0.001). Conclusions: there is an association between PTT goals and the development of hemorrhagic complications; The risk of presenting hemorrhagic complications increases 2.97 times when maintaining PPT goals >70 seconds during ECMO support. Not using UFH during ECMO support and anticoagulation with goals greater than 60 seconds clinically increases the risk of hemorrhagic events. Therefore, the recommendation is to maintain a maximum PTT of 70 seconds with or without UFH during ECMO support in adults. | eng |
dc.description.degreelevel | Maestría | spa |
dc.description.degreename | Magíster en Ciencias Epidemiología Clínica | spa |
dc.description.methods | Estudio cuantitativo, observacional y analítico de cohorte retrospectivo | spa |
dc.format.extent | x, 97 páginas | spa |
dc.format.mimetype | application/pdf | spa |
dc.identifier.instname | Universidad Nacional de Colombia | spa |
dc.identifier.reponame | Repositorio Institucional Universidad Nacional de Colombia | spa |
dc.identifier.repourl | https://repositorio.unal.edu.co/ | spa |
dc.identifier.uri | https://repositorio.unal.edu.co/handle/unal/86526 | |
dc.language.iso | spa | spa |
dc.publisher | Universidad Nacional de Colombia | spa |
dc.publisher.branch | Universidad Nacional de Colombia - Sede Bogotá | spa |
dc.publisher.faculty | Facultad de Medicina | spa |
dc.publisher.place | Bogotá, Colombia | spa |
dc.publisher.program | Bogotá - Medicina - Maestría en Epidemiología Clínica | spa |
dc.relation.indexed | Bireme | spa |
dc.relation.references | Asociación Médica Mundial. (2013). Declaración de HELSINKI de la AMM. In 64a Asamblea General. 64a Asamblea General. | spa |
dc.relation.references | Barton, R., Ignjatovic, V., & Monagle, P. (2019). Anticoagulation during ECMO in neonatal and paediatric patients. Thrombosis Research, 173. https://doi.org/10.1016/j.thromres.2018.05.009 | spa |
dc.relation.references | Bikdeli, B., Talasaz, A. H., Rashidi, F., Bakhshandeh, H., Rafiee, F., Rezaeifar, P., Baghizadeh, E., Matin, S., Jamalkhani, S., Tahamtan, O., Sharif-Kashani, B., Beigmohammadi, M. T., Farrokhpour, M., Sezavar, S. H., Payandemehr, P., Dabbagh, A., Moghadam, K. G., Khalili, H., Yadollahzadeh, M., … Sadeghipour, P. (2022). Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial. Thrombosis and Haemostasis, 122(1), 131–141. https://doi.org/10.1055/A-1485-2372 | spa |
dc.relation.references | Burša, F., Sklienka, P., Frelich, M., Jor, O., Ekrtová, T., & Máca, J. (2022). Anticoagulation Management during Extracorporeal Membrane Oxygenation—A Mini-Review. Medicina (Lithuania), 58(12), 1783. https://doi.org/10.3390/MEDICINA58121783 | spa |
dc.relation.references | Cartwright, B., Bruce, H. M., Kershaw, G., Cai, N., Othman, J., Gattas, D., Robson, J. L., Hayes, S., Alicajic, H., Hines, A., Whyte, A., Chaikittisilpa, N., Southwood, T. J., Forrest, P., Totaro, R. J., Bannon, P. G., Dunkley, S., Chen, V. M., & Dennis, M. (2021). Hemostasis, coagulation and thrombin in venoarterial and venovenous extracorporeal membrane oxygenation: the HECTIC study. Scientific Reports, 11(1), 7975. https://doi.org/10.1038/S41598-021-87026-Z | spa |
dc.relation.references | Cashen, K., Meert, K., & Dalton, H. (2019). Anticoagulation in Neonatal ECMO: An Enigma Despite a Lot of Effort! In Frontiers in Pediatrics (Vol. 7, Issue 366). https://doi.org/10.3389/fped.2019.00366 | spa |
dc.relation.references | Cécile Aubron, Zoe McQuilten, Michael Bailey, Jasmin Board, Heidi Buhr, Bruce Cartwright, Mark Dennis, Carol Hodgson, & Paul Forrest. (2019). Low-Dose Versus Therapeutic Anticoagulation in Patients on Extracorporeal Membrane Oxygenation: A Pilot Randomized Trial. Critical Care Medicine, 47(7), 563–571. | spa |
dc.relation.references | Chlebowski, M. M., Baltagi, S., Carlson, M., Levy, J. H., & Spinella, P. C. (2020). Clinical controversies in anticoagulation monitoring and antithrombin supplementation for ECMO. In Critical Care (Vol. 24, Issue 1). https://doi.org/10.1186/s13054-020-2726-9 | spa |
dc.relation.references | Chung, M., Cabezas, F. R., Nunez, J. I., Kennedy, K. F., Rick, K., Rycus, P., Mehra, M. R., Garan, A. R., Kociol, R. D., & Grandin, E. W. (2020). Hemocompatibility-Related Adverse Events and Survival on Venoarterial Extracorporeal Life Support: An ELSO Registry Analysis. JACC: Heart Failure, 8(11), 892–902. https://doi.org/10.1016/j.jchf.2020.09.004 | spa |
dc.relation.references | Ciapponi A. (2018). AMSTAR-2: herramienta de evaluación crítica de revisiones sistemáticas de estudios de intervenciones de salud. EVIDENCIA - Actualización En La Práctica Ambulatoria, 21(1), 1–13. www.evidencia.org.ar | spa |
dc.relation.references | Colman, E., Yin, E. B., Laine, G., Chatterjee, S., Saatee, S., Herlihy, J. P., Reyes, M. A., & Bracey, A. W. (2019). Evaluation of a heparin monitoring protocol for extracorporeal membrane oxygenation and review of the literature. Journal of Thoracic Disease, 11(8), 3325–3335. https://doi.org/10.21037/JTD.2019.08.44 | spa |
dc.relation.references | Combes, A., Peek, G. J., Hajage, D., Hardy, P., Abrams, D., Schmidt, M., Dechartres, A., & Elbourne, D. (2020). ECMO for severe ARDS: systematic review and individual patient data meta-analysis. Intensive Care Medicine, 46(11), 2048–2057. https://doi.org/10.1007/s00134-020-06248-3 | spa |
dc.relation.references | Descamps, R., Moussa, M. D., Besnier, E., Fischer, M. O., Preau, S., Tamion, F., Daubin, C., Cousin, N., Vincentelli, A., Goutay, J., & Du Cheyron, D. (2021). Anti-Xa activity and hemorrhagic events under extracorporeal membrane oxygenation (ECMO): a multicenter cohort study. Critical Care, 25(1). https://doi.org/10.1186/S13054-021-03554-0 | spa |
dc.relation.references | Díaz, R., Fajardo, C., & Rufs, J. (2017). Historia del ECMO (oxigenación por membrana extracorpórea o soporte vital extracorpóreo). Revista Medica Clinica Las Condes, 28(5), 796–802. https://doi.org/10.1016/J.RMCLC.2017.10.004 | spa |
dc.relation.references | Doymaz, S. (2018). Anticoagulation during ECMO: The Past, Present and Future. Journal of Intensive and Critical Care, 4(2). https://doi.org/10.21767/2471-8505.100114 | spa |
dc.relation.references | ELSO. (2017). ELSO Guidelines for Cardiopulmonary Extracorporeal Life Support. Extracorporeal Life Support Organization. Versión 1.4. https://www.elso.org/ecmo-resources/elso-ecmo-guidelines.aspx | spa |
dc.relation.references | Esper, S. A., Welsby, I. J., Subramaniam, K., John Wallisch, W., Levy, J. H., Waters, J. H., Triulzi, D. J., Hayanga, J. W. A., & Schears, G. J. (2017). Adult extracorporeal membrane oxygenation: an international survey of transfusion and anticoagulation techniques. Vox Sanguinis, 112(5), 443–452. https://doi.org/10.1111/vox.12514 | spa |
dc.relation.references | Fernández-Mondéjar, E., Fuset-Cabanes, M. P., Grau-Carmona, T., López-Sánchez, M., Peñuelas, Pérez-Vela, J. L., Pérez-Villares, J. M., Rubio-Muñoz, J. J., & Solla-Buceta, M. (2019). Empleo de ECMO en UCI. Recomendaciones de la Sociedad Española de Medicina Intensiva Crítica y Unidades Coronarias. Medicina Intensiva, 43(2), 108–120. https://doi.org/10.1016/J.MEDIN.2018.09.017 | spa |
dc.relation.references | Figueredo, A., Salazar, L., Pizarro, C., Orozco-Levi, M., & Botia, M. (2020). Experience with veno-venous ecmo in patients with adult respiratory distress syndrome secondary to viral pneumonia. Case series. Colomb. J. Anesthesiol, 48(4). https://www.revcolanest.com.co/index.php/rca/article/view/933 | spa |
dc.relation.references | Fitousis, K., Klasek, R., Mason, P. E., & Masud, F. (2016). Evaluation of a pharmacy managed heparin protocol for extracorporeal membrane oxygenation patients. Http://Dx.Doi.Org/10.1177/0267659116678057, 32(3), 238–244. https://doi.org/10.1177/0267659116678057 | spa |
dc.relation.references | Freedman, L. (1982). Tables of the number of patients required in clinical trials using the logrank test. Statistics in Medicine. | spa |
dc.relation.references | Friedrichson, B., Mutlak, H., Zacharowski, K., & Piekarski, F. (2021). Insight into ECMO, mortality and ARDS: a nationwide analysis of 45,647 ECMO runs. Critical Care (London, England), 25(1). https://doi.org/10.1186/S13054-021-03463-2 | spa |
dc.relation.references | Fundación Clínica Shaio. (2021). Protocolo de atención a pacientes con terapia de oxigenación extracorpórea (ECMO). In Protocolos institucionales: Vol. Versión 1 (pp. 10–11). | spa |
dc.relation.references | Garrahan Juan P, & Bonduel M. (2018). Desafíos en el manejo antitrombótico de oxigenadores extracorpóreos de membrana y dispositivos intraventriculares. Hemotología, 22, 98–104. | spa |
dc.relation.references | Hsieh, F., & Lavori, P. (2000). Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates. Controlled Clinical Trials . | spa |
dc.relation.references | Kaseer, H., Soto-Arenall, M., Sanghavi, D., Moss, J., Ratzlaff, R., Pham, S., & Guru, P. (2020). Heparin vs bivalirudin anticoagulation for extracorporeal membrane oxygenation. Journal of Cardiac Surgery, 35(4), 779–786. https://doi.org/10.1111/jocs.14458 | spa |
dc.relation.references | Lv, X., Deng, M., Wang, L., Dong, Y., Chen, L., & Dai, X. (2021). Low vs standardized dose anticoagulation regimens for extracorporeal membrane oxygenation: A meta-analysis. PLoS ONE, 16(4 April). https://doi.org/10.1371/journal.pone.0249854 | spa |
dc.relation.references | Mazzeffi, M. A., Tanaka, K., Roberts, A., Rector, R., Menaker, J., Kon, Z., Deatrick, K. B., Kaczorowski, D., Griffith, B., & Herr, D. (2019). Bleeding, Thrombosis, and Transfusion With Two Heparin Anticoagulation Protocols in Venoarterial ECMO Patients. Journal of Cardiothoracic and Vascular Anesthesia, 33(5), 1216–1220. https://doi.org/10.1053/J.JVCA.2018.07.045 | spa |
dc.relation.references | McMichael, A. B. V., Ryerson, L. M., Ratano, D., Fan, E., Faraoni, D., & Annich, G. M. (2022). 2021 ELSO Adult and Pediatric Anticoagulation Guidelines. ASAIO Journal, 68(3), 303–310. https://doi.org/10.1097/MAT.0000000000001652 | spa |
dc.relation.references | Millar, J. E., Bartnikowski, N., von Bahr, V., Malfertheiner, M. V., Obonyo, N. G., Belliato, M., Suen, J. Y., Combes, A., McAuley, D. F., Lorusso, R., & Fraser, J. F. (2019). Extracorporeal membrane oxygenation (ECMO) and the acute respiratory distress syndrome (ARDS): a systematic review of pre-clinical models. Intensive Care Medicine Experimental , 7(1), 18. https://doi.org/10.1186/S40635-019-0232-7 | spa |
dc.relation.references | Ministerio de Protección Social. (2008). Resolución Número 2378 de 2008. S Buenas Prácticas Clínicas Para Las Instituciones Que Conducen Investigación Con Medicamentos En Seres Humanos, 1–93. | spa |
dc.relation.references | Ministerio de Salud. (1993). Resolución número 8430 DE 1993. 28/06/2022https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/DIJ/RESOLUCION-8430-DE-1993.PDF | spa |
dc.relation.references | Nunez, J. I., Gosling, A. F., O’Gara, B., Kennedy, K. F., Rycus, P., Abrams, D., Brodie, D., Shaefi, S., Garan, A. R., & Grandin, E. W. (2022). Bleeding and thrombotic events in adults supported with venovenous extracorporeal membrane oxygenation: an ELSO registry analysis. Intensive Care Medicine, 48(2), 213–224. https://doi.org/10.1007/s00134-021-06593-x | spa |
dc.relation.references | Olson, S. R., Murphree, C. R., Zonies, D., Meyer, A. D., McCarty, O. J. T., Deloughery, T. G., & Shatzel, J. J. (2021). Thrombosis and Bleeding in Extracorporeal Membrane Oxygenation (ECMO) Without Anticoagulation: A Systematic Review. ASAIO Journal, 67(3), 290–296. https://doi.org/10.1097/MAT.0000000000001230 | spa |
dc.relation.references | Oude Lansink-Hartgring, A., de Vries, A. J., Droogh, J. M., & van den Bergh, W. M. (2019). Hemorrhagic complications during extracorporeal membrane oxygenation – The role of anticoagulation and platelets. Journal of Critical Care, 54, 239–243. https://doi.org/https://doi.org/10.1016/j.jcrc.2019.09.013 | spa |
dc.relation.references | Pooboni, S. K., & Gulla, K. M. (2021). Vascular access in ECMO. In Indian Journal of Thoracic and Cardiovascular Surgery (Vol. 37, Issue 2, pp. 221–231). https://doi.org/10.1007/s12055-020-00999-w | spa |
dc.relation.references | Popugaev, K. A., Bakharev, S. A., Kiselev, K. V., Samoylov, A. S., Kruglykov, N. M., Abudeev, S. A., Zhuravel, S. V., Shabanov, A. K., Mueller, T., Mayer, S. A., & Petrikov, S. S. (2020). Clinical and pathophysiologic aspects of ECMO-associated hemorrhagic complications. PloS One, 15(10). https://doi.org/10.1371/JOURNAL.PONE.0240117 | spa |
dc.relation.references | Rivosecchi, R. M., Arakelians, A. R., Ryan, J., Murray, H., Ramanan, R., Gomez, H., Phillips, D., Sciortino, C., Arlia, P., Freeman, D., Sappington, P. L., & Sanchez, P. G. (2021). Comparison of Anticoagulation Strategies in Patients Requiring Venovenous Extracorporeal Membrane Oxygenation: Heparin Versus Bivalirudin∗. Critical Care Medicine, 49(7), 1129–1136. https://doi.org/10.1097/CCM.0000000000004944 | spa |
dc.relation.references | Rosa C, & Burdet J. (2020). Monitoreo de la terapia con heparina no fraccionada: el APTT tradicional versus la heparinemia por anti-Xa. Revista Hematología, 21(1), 86–92. https://revistahematologia.com.ar/index.php/Revista/article/view/139 | spa |
dc.relation.references | Sadeghipour, P., Talasaz, A. H., Rashidi, F., Sharif-Kashani, B., Beigmohammadi, M. T., Farrokhpour, M., Sezavar, S. H., Payandemehr, P., Dabbagh, A., Moghadam, K. G., Jamalkhani, S., Khalili, H., Yadollahzadeh, M., Riahi, T., Rezaeifar, P., Tahamtan, O., Matin, S., Abedini, A., Lookzadeh, S., … Bikdeli, B. (2021). Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial. JAMA, 325(16), 1620–1630. https://doi.org/10.1001/JAMA.2021.4152 | spa |
dc.relation.references | Salazar, L. A., Uribe, J. D., Poveda Henao, C. M., Santacruz, C. M., Giraldo Bejarano, E., Bautista, D. F., Rey, J. A., & Giraldo-Ramírez, N. (2021). Colombian ECMO consensus for patients with severe respiratory failure associated with COVID-19. Acta Colombiana de Cuidado Intensivo, 21(3), 272–282. https://doi.org/10.1016/J.ACCI.2020.09.001 | spa |
dc.relation.references | Seeliger, B., Döbler, M., Friedrich, R., Stahl, K., Kühn, C., Bauersachs, J., Steinhagen, F., Ehrentraut, S. F., Schewe, J.-C., Putensen, C., Welte, T., Hoeper, M. M., Tiede, A., David, S., & Bode, C. (2020). Comparison of anticoagulation strategies for veno-venous ECMO support in acute respiratory failure. https://doi.org/10.1186/s13054-020-03348-w | spa |
dc.relation.references | Sklar, M. C., Sy, E., Lequier, L., Fan, E., & Kanji, H. D. (2016). Anticoagulation Practices during Venovenous Extracorporeal Membrane Oxygenation for Respiratory Failure. A Systematic Review. Annals of the American Thoracic Society, 13(12), 2242–2250. https://doi.org/10.1513/ANNALSATS.201605-364SR | spa |
dc.relation.references | Stocker, C. F., & Horton, S. B. (2016). Anticoagulation strategies and difficulties in neonatal and paediatric extracorporeal membrane oxygenation (ECMO). In Perfusion (United Kingdom) (Vol. 31, Issue 2, pp. 95–102). https://doi.org/10.1177/0267659115590626 | spa |
dc.relation.references | Thomas, J., Kostousov, V., & Teruya, J. (2018). Bleeding and Thrombotic Complications in the Use of Extracorporeal Membrane Oxygenation. Seminars in Thrombosis and Hemostasis, 44(1), 20–29. https://doi.org/10.1055/S-0037-1606179 | spa |
dc.relation.references | Torregrosa, S., Paz Fuset, M., Castelló, A., Mata, D., Heredia, T., Bel, A., Pérez, M., & Anastasio Montero, J. (2009). Oxigenación de membrana extracorpórea para soporte cardíaco o respiratorio en adultos (Vol. 16, Issue 2). | spa |
dc.relation.references | Torres C, Samaniego G, & Cueva L. (2019). Oxigenación por membrana extracorpórea en síndrome de distrés respiratorio agudo en el adulto. Sociedad Venezolana de Farmacología Clínica y Terapéutica, 38(6), 772–777. https://www.redalyc.org/journal/559/55964142017/html/ | spa |
dc.relation.references | Yeo, H. J., Jeon, D., Kim, Y. S., Cho, W. H., & Kim, D. (2016). Veno-veno-arterial extracorporeal membrane oxygenation treatment in patients with severe acute respiratory distress syndrome and septic shock. In Critical Care (Vol. 20, Issue 1). https://doi.org/10.1186/s13054-016-1205-9 | spa |
dc.relation.references | Zapol, W. M., Snider, M. T., Hill, J. D., Fallat, R. J., Bartlett, R. H., Edmunds, L. H., Morris, A. H., Peirce, E. C., Thomas, A. N., & Proctor, H. J. (1979). Extracorporeal membrane oxygenation in severe acute respiratory failure: a randomized prospective study. JAMA, 242(20), 2193–2196. | spa |
dc.rights.accessrights | info:eu-repo/semantics/openAccess | spa |
dc.rights.license | Atribución-NoComercial-CompartirIgual 4.0 Internacional | spa |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | spa |
dc.subject.ddc | 610 - Medicina y salud::615 - Farmacología y terapéutica | spa |
dc.subject.decs | Oxigenación por Membrana Extracorpórea/efectos adversos | spa |
dc.subject.decs | Extracorporeal Membrane Oxygenation/adverse effects | eng |
dc.subject.decs | Tiempo de Tromboplastina Parcial | spa |
dc.subject.decs | Partial Thromboplastin Time | eng |
dc.subject.decs | Anticoagulantes | spa |
dc.subject.decs | Anticoagulants | eng |
dc.subject.proposal | ECMO | spa |
dc.subject.proposal | Anticoagulación | spa |
dc.subject.proposal | Complicación hemorrágica | spa |
dc.subject.proposal | Heparina no fraccionada | spa |
dc.subject.proposal | Tiempo parcial de tromboplastina | spa |
dc.subject.proposal | ECMO | eng |
dc.subject.proposal | Anticoagulation | eng |
dc.subject.proposal | Hemorrhagic complication | eng |
dc.subject.proposal | Unfractionated heparin | eng |
dc.subject.proposal | Partial thromboplastin time | eng |
dc.title | Asociación entre la anticoagulación bajo diferentes rangos de tiempo parcial de tromboplastina (PTT) y el desarrollo de complicaciones hemorrágicas en adultos durante el soporte de oxigenación por membrana extracorpórea (ECMO). Un estudio de cohorte retrospectivo | spa |
dc.title.translated | Association between anticoagulation under different partial thromboplastin time (PTT) ranges and the development of hemorrhagic complications in adults during extracorporeal membrane oxygenation (ECMO) support. A retrospective cohort study | eng |
dc.type | Trabajo de grado - Maestría | spa |
dc.type.coar | http://purl.org/coar/resource_type/c_bdcc | spa |
dc.type.coarversion | http://purl.org/coar/version/c_ab4af688f83e57aa | spa |
dc.type.content | Text | spa |
dc.type.driver | info:eu-repo/semantics/masterThesis | spa |
dc.type.redcol | http://purl.org/redcol/resource_type/TM | spa |
dc.type.version | info:eu-repo/semantics/acceptedVersion | spa |
dcterms.audience.professionaldevelopment | Estudiantes | spa |
dcterms.audience.professionaldevelopment | Investigadores | spa |
dcterms.audience.professionaldevelopment | Maestros | spa |
dcterms.audience.professionaldevelopment | Público general | spa |
oaire.accessrights | http://purl.org/coar/access_right/c_abf2 | spa |
Archivos
Bloque original
1 - 1 de 1
Cargando...
- Nombre:
- 1019126682.2024.pdf
- Tamaño:
- 2.36 MB
- Formato:
- Adobe Portable Document Format
- Descripción:
- Tesis de Maestría en Epidemiología Clínica
Bloque de licencias
1 - 1 de 1
No hay miniatura disponible
- Nombre:
- license.txt
- Tamaño:
- 5.74 KB
- Formato:
- Item-specific license agreed upon to submission
- Descripción: